Author

D. Largaespada

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Approach:biophysical modeling· 1 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Assay:CRISPR screen· 1

Frequent Co-Authors

A. Aguilera· 1 shared B. Moriarity· 1 shared B. S. Moriarity· 1 shared B. Smeester· 1 shared D. Odde· 1 shared D. Wood· 1 shared E. Law· 1 shared E. Pomeroy· 1 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Aguilera

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Indirect CRISPR screening with photoconversion revealed key factors of drug resistance with cell-cell interactions

K. Sugita, I. Onishi, R. Nakayama, S. Ishibashi, M. Ikeda, M. Inoue, R. Narita, S. Oshima, K. Shimizu, S. Saito, S. Sato, B. S. Moriarity, K. Yamamoto, D. Largaespada, M. Kitagawa, M. Kurata

This study uses indirect CRISPR screening with photoconversion to identify key factors of drug resistance mediated by cell-cell interactions, finding genes that reduce cancer cell apoptosis when knocked out in supporting cells.

bioRxiv · Jul 15, 2022Cancer Biology

APOBEC3A Catalyzes Mutation and Drives Carcinogenesis In Vivo

E. Law, R. Levin-Klein, M. Jarvis, H. Kim, P. Argyris, M. Carpenter, G. Starrett, L. Larson, M. Burns, R. Vogel, S. Stavrou, A. Aguilera, S. Wagner, D. Largaespada, T. Starr, , R. Harris

This study shows APOBEC3A promotes tumorigenesis in mice and supports its role in causing mutations in human cancers.

bioRxiv · Dec 27, 2019Cancer Biology

SEMA4C is a novel target to limit osteosarcoma growth, progression, and metastasis

B. Smeester, N. Slipek, E. Pomeroy, H. Bomberger, G. Shamsan, J. Peterson, M. Crosby, G. Draper, K. Becklin, E. Rahrmann, J. McCarthy, D. Odde, D. Wood, D. Largaespada, B. Moriarity

This study shows SEMA4C promotes osteosarcoma growth and metastasis, with its inhibition reducing tumor progression and suggesting clinical potential.

bioRxiv · Jan 14, 2019Cancer Biology